All News
Did you know?
👉APOL1 variants are protective against trypanosomiasis.
👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had:
⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
TheDaoIndex KDAO2011 ( View Tweet)
Abs#0726 #ACR23 @RheumNow
MSUS recs in Canadian Rheum training 🇨🇦:
Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn
Limited MSUS of knee/ankle for effusion
@USSONAR_Rh @MymaAlbaydaMD
Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V
Eric Dein ( View Tweet)
Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
Richard Conway ( View Tweet)
Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 @ACRheum @RheumNow #RheumEd #POCUS https://t.co/mqdcPEeMYW
Janet Pope ( View Tweet)
INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a
Richard Conway ( View Tweet)
Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23
Janet Pope ( View Tweet)
A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt
Janet Pope ( View Tweet)
A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W
TheDaoIndex KDAO2011 ( View Tweet)
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE:
⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS
Key message? Addt'l tx needed to avoid high GC doses
#ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
CV events in women w/ ARDs pregnancies:
-2.0% of 19,340 pregnant ARDs
Adjusted relative risk:
-4 fold in ARD
-15 fold in primary APS
-6 fold in SLE
-SLE + APS 18 fold
25-30% occur in early post partum!
Need for continued vigilance after delivery
@RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm ( View Tweet)
CVE’s higher in pregnant pts with SLE + APS, primary APS and Lupus nephritis especially in the postpartum period. Rheums need to be involved with their patients’ care during pregnancy! Abstr#0722 #ACr23 @rheumnow https://t.co/P6sbJtd6xW
TheDaoIndex KDAO2011 ( View Tweet)
Always great to see UCSD represent at #ACR23!
Pregnant women with rheumatic diseases and antiphospholipid syndrome higher a HIGHER risk for acute cardiovascular events
30% of events occurred postpartum
@RheumNow Abs#0722 https://t.co/CqZedfOlBC
Robert B Chao, MD ( View Tweet)
#ACR23 Real-world multicentre study showed steroid-sparing effect of Belimumab in #SLE. At 2 years, proportion of patients on =>10mg/d decreased from 52% to 3%. 18% and 13% achieved LLDAS and DORIS remission. Support its use esp. in those relying on glucocorticoids @RheumNow https://t.co/ad5XH3pmYc
Md Yuzaiful Md Yusof ( View Tweet)
Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects
Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi
@RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6
Robert B Chao, MD ( View Tweet)
#ACRBest @RheumNow https://t.co/u6DiQbebTF
Aurelie Najm ( View Tweet)
Plenary 1 #ACR23
CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko
Bella Mehta bella_mehta ( View Tweet)
Treatment intensification was associated with a higher ASDAS cut-off (2.7) value than the recommended one (≥2.1), the recommended cut-off could be too stringent or consider other factors than disease activity, Webers, El-Din Abst#0517 #ACR23 @RheumNow https://t.co/ZtBXhufxU1 https://t.co/MzvZQoFbvw
Dr. Antoni Chan ( View Tweet)
Should all of active moms with #SLE receive DVT prophylaxis post partum? High rates of VTE in #ARDs post partum #0722 #ACRbest #ACR23 @RheumNow @ACRheum Likely data driven by #SLE and maybe #RA and not all #autoimmune #rheumatic #disease. Large pop’n data from California https://t.co/sGJa5N6HUj
Janet Pope ( View Tweet)
Plenary talk by Dhital etc al, shows increased risk of acute CV events in pregnant rheumatic, SLE, APS pts, esp if nephritis or APL+. #ACR23 Abstract 0722 https://t.co/pG0PqzVtIU
Dr. John Cush RheumNow ( View Tweet)